China

Astellas announced that China NMPA approved XTANDI for the treatment of prostate cancer

The FINANCIAL — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the China National Medical Products Administration (NMPA) has approved XTANDI® (enzalutamide soft capsules) for the treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) with high
November 6, 2020
2 mins read

FMCG in China is on the road to recovery

The FINANCIAL — The total spending on fast-moving consumer goods (FMCG) in China grew by 4.1% in the 12 weeks to 11 September 2020 compared to the same period last year. Stronger growth in lower-tier cities and ecommerce channels remained the key
November 2, 2020
2 mins read
1 2 3 … 6

Get updates

Join

We hate spams like you do

Latest comments

Go toTop